Anti-CTGF (Pamrevlumab), Human IgG1 Antibody

Anti-CTGF (Pamrevlumab), Human IgG1 Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a fully human IgG1 monoclonal antibody that is directed against connective tissue growth factor (CTGF). CTGF is a cysteine-rich glycoprotein that is found in several cell types such as fibroblasts, smooth muscle cells, and cartilaginous cells. It is known to be involved in multiple pathological and biological processes such as angiogenesis, tumor development, skin diseases, and osteogenesis. Studies have demonstrated that increased CTGF expression is found in fibrotic lesions, which suggests its role in causing fibrosis. Fibrosis is one of the hallmarks of muscular dystrophies, resulting in weakness and injury of the muscles. Increased expression of CTGF is also observed in muscular dystrophies. Binding of the antibody to CTGF decreases fibrosis in muscles and improves the function of the muscles. The original monoclonal antibody received Fast Track designation from the FDA to treat idiopathic pulmonary fibrosis (IPF) and pancreatic cancer. Currently, the original antibody is undergoing clinical trials to treat Duchenne muscular dystrophy.

Immunogen Sequence:Human CTGF

Target Alternative Name:CCN2, NOV2, HCS24, IGFBP8, IGFBP-8, IBP-8, IGF-Binding Protein 8, CCN Family Member 2

Species Reactivities:/

Tag Line:The biosimilar is a human monoclonal antibody that targets CTGF, a pro-inflammatory protein that plays a key role in the progression of fibrosis and other proliferation disorders

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.